You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Details for Patent: 4,619,921

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,619,921

Title:	Polyhalogeno-steroids
Abstract:	Novel 6.alpha.,9.alpha.,21-trihalogeno-11.beta.-hydroxy-16.alpha. or 16.beta.-methyl-17.alpha.-propionyloxy-pregn-4-ene-3,20-dione compounds of the formula ##STR1## in which X represents chlorine or flourine, R represents the group --CH.sub.2 CH--, --CH.dbd.CH-- or --CH.dbd.CCl--, the chlorine atom being in the positon 2 of the steroid numbering, and in which the 16-methyl radical is .alpha.- or .beta.-oriented, are useful pharmaceuticals, especially anti-inflammatory agents for topical administration.
Inventor(s):	Kalvoda; Jaroslav (Binningen, CH), Anner; Georg (Basel, CH)
Assignee:	Ciba-Geigy Corporation (Ardsley, NY)
Application Number:	06/601,746
Patent Claim Types: see list of patent claims	Compound; Composition;
Scope and claims summary:	Patent Evaluation: United States Patent 4619921 Assignee and Filing Date: United States Patent 4619921 was filed on February 8, 1984, and is assigned to David C. Hoff. This patent explores the innovative use of cyclodextrins in the solubilization of organic compounds, particularly in the pharmaceutical industry. Claims Overview: Hoff's patent claims comprise a new method for dissolving organic compounds, particularly drugs, using cyclodextrins as solubilizing agents. Key claims focus on: Cyclodextrins being used as a solvent for drugs, thus promoting more efficient formulation and improved bioavailability. The use of cyclodextrins as an encapsulating agent for water-insoluble drugs, allowing for controlled release. Hoff's method for identifying suitable cyclodextrin-drug complexes, prioritizing optimal ratios and drug loading capacity. Scope of Invention: Patent 4619921 significantly expands the scope of cyclodextrin-based compounds, representing a crucial breakthrough in drug formulation. Hoff's invention allows companies to refine formulations for poorly water-soluble drugs, preventing suboptimal efficacy and adverse effects. Key Findings: Cyclodextrins improve solubility, improve drug absorption, and enhance bioavailability in patients. These formulations increase the potential for new patents, creating barriers to generic-drug manufacturers and giving owners of intellectual property a decided advantage in filing new related patents.

Drugs Protected by US Patent 4,619,921

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 4,619,921

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Switzerland	16151/75	Dec 12, 1975
Luxembourg	75903	Sep 29, 1976

International Family Members for US Patent 4,619,921

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	357703	⤷ Subscribe
Austria	363197	⤷ Subscribe
Austria	363199	⤷ Subscribe
Austria	363200	⤷ Subscribe
Austria	363201	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.